Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis

다국어 초록 (Multilingual Abstract)

Background: Romosozumab has shown significant improvement in bone mineral density (BMD) in previously reported trials. However, BMD reflects only bone strength and does not offer insight into the bone microarchitecture. The trabecular bone score (TBS) is a non-invasive tool used to assess bone microarchitecture. Several previous studies have evaluated the efficacy of anti-osteoporotic agents using the TBS. However, data regarding the potency of romosozumab based on the TBS is lacking. This retrospective observational cohort study demonstrated the impact of romosozumab use on the TBS. Methods: The primary outcome was the percentage change in the TBS from baseline to post-treatment. Postmenopausal osteoporosis patients were followed up for 6 and 12 months after romosozumab (210 mg monthly, N =10) and denosumab (60 mg every 6 months, N=21) or ibandronate (150 mg monthly, N=24) treatments, respectively. Patients who had previously used osteoporosis medications were included, if any the washout period was sufficient. Results: The percentage change in TBS from baseline to post-treatment was 2.53±2.98% (6 months, N=10; P=0.04), 0.59%±3.26% (12 months, N=21; P=0.48), and -0.45±3.66% (12 months, N=24; P=0.51) in the romosozumab, denosumab, and ibandronate groups, respectively. Romosozumab demonstrated a noticeable increase in TBS, although it did not reach the least significant change (5.8%) in TBS. Conclusions: Romosozumab improved the TBS in postmenopausal women with osteoporosis. TBS may be potentially useful for monitoring romosozumab treatment.

참고문헌 (Reference)

1 Kenneth G. Saag, "Trabecular bone score in patients with chronic glucocorticoid therapy-induced osteoporosis treated with alendronate or teriparatide" Wiley 68 (68): 2122-2128, 2016

2 S. Boutroy, "Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study" Springer Science and Business Media LLC 24 (24): 77-85, 2013

3 Barbara C Silva, "Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image" Wiley 29 (29): 518-530, 2014

4 J. Ramalho, "The trabecular bone score: Relationships with trabecular and cortical microarchitecture measured by HR-pQCT and histomorphometry in patients with chronic kidney disease" Elsevier BV 116 : 215-220, 2018

5 Xiaofeng Li, "Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling" Elsevier BV 280 (280): 19883-19887, 2005

6 Felicia Cosman, "Romosozumab treatment in postmenopausal women with osteoporosis" Massachusetts Medical Society 375 (375): 1532-1543, 2016

7 Kenneth G. Saag, "Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis" Massachusetts Medical Society 377 (377): 1417-1427, 2017

8 Michael R. McClung, "Romosozumab in Postmenopausal Women with Low Bone Mineral Density" Massachusetts Medical Society 370 (370): 412-420, 2014

9 L. M. Del Rio, "Is bone microarchitecture status of the lumbar spine assessed by TBS related to femoral neck fracture? A Spanish case-control study" Springer Science and Business Media LLC 24 (24): 991-998, 2013

10 Barbara C. Silva, "Fracture Risk Prediction by Non-BMD DXA Measures: the 2015 ISCD Official Positions Part 2: Trabecular Bone Score" Elsevier BV 18 (18): 309-330, 2015

11 J. Touvier, "Fracture Discrimination by Combined Bone Mineral Density (BMD) and Microarchitectural Texture Analysis" Springer Science and Business Media LLC 96 (96): 274-283, 2015

12 T.P van Staa, "Epidemiology of fractures in England and Wales" Elsevier BV 29 (29): 517-522, 2001

13 Albrecht W Popp, "Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study" Wiley 28 (28): 449-454, 2013

14 R. Rizzoli, "Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study" Springer Science and Business Media LLC 23 (23): 305-315, 2012

15 Carolina A. Moreira, "Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial" Elsevier BV 97 : 314-319, 2017

16 M. R. McClung, "Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis" Springer Science and Business Media LLC 28 (28): 2967-2973, 2017

17 Kelly Krohn, "Dual-energy X-ray Absorptiometry Monitoring with Trabecular Bone Score: 2019 ISCD Official Position" Elsevier BV 22 (22): 501-505, 2019

18 Monique Arlot, "Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters" Wiley 20 (20): 1244-1253, 2005

19 Didier Hans, "Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae" Elsevier BV 14 (14): 302-312, 2011

20 Laurent Pothuaud, "Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture" Elsevier BV 42 (42): 775-787, 2008

21 E. Leib, "Comparing Bone Microarchitecture by Trabecular Bone Score (TBS) in Caucasian American Women with and Without Osteoporotic Fractures" Springer Science and Business Media LLC 95 (95): 201-208, 2014

22 C. Senn, "Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study" Springer Science and Business Media LLC 25 (25): 1945-1951, 2014

23 Pascale Chavassieux, "Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: Bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment" Wiley 34 (34): 1597-1608, 2019

24 Didier Hans, "Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study" Wiley 26 (26): 2762-2769, 2011

25 Luca Dalle Carbonare, "Bone microarchitecture as an important determinant of bone strength" Springer Science and Business Media LLC 27 (27): 99-105, 2004

26 Ego Seeman, "Bone Quality — The Material and Structural Basis of Bone Strength and Fragility" Massachusetts Medical Society 354 (354): 2250-2261, 2006

27 Jung Hee Kim, "Application of the Trabecular Bone Score in Clinical Practice" 대한골대사학회 28 (28): 101-113, 2021

28 K. Nassar, "Added value of trabecular bone score over bone mineral density for identification of vertebral fractures in patients with areal bone mineral density in the non-osteoporotic range" Springer Science and Business Media LLC 25 (25): 243-249, 2014

29 J. P. Bilezikian, "Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial" Springer Science and Business Media LLC 29 (29): 323-328, 2018

30 Majumdar S, "A review of magnetic resonance(MR)imaging of trabecular bone micro-architecture : contribution to the prediction of biomechanical properties and fracture prevalence" 6 : 321-327, 1998

31 Renaud Winzenrieth, "A retrospective case-control study assessing the role of trabecular bone score in postmenopausal Caucasian women with osteopenia: analyzing the odds of vertebral fracture" Springer Science and Business Media LLC 86 (86): 104-109, 2010

32 Bénédicte Rabier, "A multicentre, retrospective case-control study assessing the role of trabecular bone score (TBS) in menopausal Caucasian women with low areal bone mineral density (BMDa): Analysing the odds of vertebral fracture" Elsevier BV 46 (46): 176-181, 2010

33 Eugene V McCloskey, "A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX" Wiley 31 (31): 940-948, 2016